Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 26, 2016

View Archived Issues

Cancer Research Technology announces ENPP2 inhibitors

Rugen Holdings reports NR2B receptor antagonists

USPI reports successful completion of preclinical testing of PROACT-D

Galectin's GR-MD-02 doesn't perform well enough in phase IIa trial

Mitsubishi Tanabe files application in Japan for combination drug for type 2 diabetes mellitus

Lundbeck updates progress of second quarter 2016

Novartis presents novel series of small molecule CSN5 inhibitors for the treatment of cancer

Suven describes novel series of amides as 5-HT4 receptor agonists for the treatment of AD

Immunovaccine releases new data from phase I/Ib study of DPX-Survivac in ovarian cancer

Sorrento Therapeutics discloses anti-HER2 antibody-anthracycline conjugates

FDA clears IND for phase I trial of DeuteRx's DRX-065

Immunophotonics doses first patient in trial of inCVAX

U.S. government contract supports Chembio Diagnostics' development of Zika point-of-care tests

Janssen describes novel tau protein PET imaging ligand [18F]JNJ-311 at ACS

BioLineRx enters joint venture with I-Bridge Capital

Factor IXa inhibitor CFM-184 shows anticoagulant potential

Positive results for Armetheon's phase I trial of tecarfarin

Lee's Pharmaceutical and Beijing Shenogen Pharma collaborate on combination product in China

Neuroderm starts enrollment in phase III trial of ND-0612L

FDA grants fast track status to Mallinckrodt's Synacthen Depot

Researchers from Genentech identify novel potent and selective NIK inhibitors

EXPAND phase III study meets its primary endpoint

Biotie Therapies' BTT-1023 receives FDA orphan drug designation

FDA grants orphan drug designation to TG Therapeutics' ublituximab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...